Drug profile · INN
lumasiran
OXLUMO
lumasiran (OXLUMO) is a hydroxyacid oxidase 1 mrna rnai inhibitor. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved Alimentary tract and metabolism (A16) A16AX18
Patents linked 0
Pipeline programs 6
News articles 1
Drug details — lumasiran
- Class
- Alimentary tract and metabolism (A16)
- Route
- —
- Patents
- 0
- Programs
- 6
- Data quality
- 0.89
Quick answer
lumasiran (OXLUMO) is a hydroxyacid oxidase 1 mrna rnai inhibitor. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN lumasiran
Brand OXLUMO
Mechanism Hydroxyacid oxidase 1 mRNA RNAi inhibitor
Therapeutic class Alimentary tract and metabolism (A16)
ATC code A16AX18
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Hydroxyacid oxidase 1 mRNA RNAi inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lumasiran?
lumasiran (OXLUMO) is a hydroxyacid oxidase 1 mrna rnai inhibitor. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for lumasiran?
OXLUMO is a marketed brand name for lumasiran. Check FDA Drugs@FDA for the current US label holder and prescribing information.